A
Atom Bioscience
Developing 1.1 category innovative drugs with global commercial value and global competitiveness for the treatment of metabolic diseases and tumors
About Atom Bioscience
Atom Bioscience is a biotech startup focused on the development of innovative treatments for chronic gout, a type of inflammatory arthritis. The company operates in the pharmaceutical market, specifically in the area of rheumatology. Their primary product is a new investigational drug, ABP-671, which has shown promising results in Phase 2a clinical trials. The drug works by reducing uric acid levels in the body, a key factor in the development of gout.
The company's target clients are individuals suffering from chronic gout, a condition that is often misunderstood and stigmatized. Atom Bioscience aims to change the perception of gout, emphasizing that it is more related to genetics than lifestyle choices.
The business model of Atom Bioscience is based on the research, development, and commercialization of pharmaceutical products. The company generates revenue through the sale of its drugs once they have been approved by regulatory bodies and are available on the market.
In summary, Atom Bioscience is a promising biotech startup with a focus on developing effective treatments for chronic gout. Their innovative approach and positive clinical trial results position them well in the pharmaceutical market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Zhenjiang, China
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 50.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Oct 2023 | $83M | $332M | Kaitai Capital · Huajin Investment · Fortune Capital · NNFE Fund Management | ↗ |
| SERIES COther financing | Jan 2022 | $45M | $180M | Kaitai Capital · Unifortune Investment · KinGray Capital · Oriza Holdings | ↗ |
Growth signals
Latest recorded traffic for Atom Bioscience is 920 monthly website visits, up 384.2% over the last three months. Atom Bioscience's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Series B and later8 investors entered at this stage
- SGShenZhen GTJA Investment Group
- UIUnifortune Investment
KinGray Capital
Oriza Holdings- ECEfung Capital
- HIHuajin Investment
- FCFortune Capital
NNFE Fund Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atom Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atom Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.